Pharmaceuticals News & Press Release Distribution

GC Biopharma celebrates 'World Hemophilia Day'

* To display a large media façade on its Yong-in R&D Center YONGIN, South Korea, April 17, 2023 /PRNewswire/ -- GC Biopharma (006280.KS), a leading provider of biopharmaceutical products inSouth Korea, takes part in a campaign to celebrate World Hemophilia Day. The company announced that a l...

2023-04-18 09:03 2463

Innovent Releases Final Analysis Results of ORIENT-16: the Phase 3 Study of Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric Cancer at the AACR Annual Meeting 2023

ROCKVILLE, Md. and SUZHOU, China, April 17, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology a...

2023-04-18 08:00 3202

Innovent Releases Final Analysis Results of ORIENT-16: the Phase 3 Study of Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric Cancer at the AACR Annual Meeting 2023

ROCKVILLE, Md. and SUZHOU, China, April 18, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology a...

2023-04-18 08:00 4170

Ocedurenone: A Novel Therapy for Uncontrolled Hypertension in Advanced Chronic Kidney Disease

PRINCETON, N.J., April 18, 2023 /PRNewswire/ -- EMJ Nephrology interviewed two World-renowned experts in nephrology and cardiology,George Bakris and Faiez Zannad, regarding the challenges of treating uncontrolled hypertension (uHTN) in patients with advanced chronic kidney disease (CKD), a large ...

2023-04-18 08:00 3391

Innovent Announces Updated Data of Phase 1 Clinical Trial for IBI351 (KRAS[G12C] Inhibitor) as Monotherapy for Solid Tumors at the AACR Annual Meeting 2023

ROCKVILLE, Md. and SUZHOU, China, April 18, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmolog...

2023-04-18 08:00 4283

Shanghai Cellular Biopharmaceutical Group presents first data from Phase I trial evaluating a novel CAR-T in advanced liver cancer at AACR Annual Meeting

Promising anti-tumor activity reported for C-CAR031, a novel Glypican 3 (GPC3)-targeting cell therapy designed by AstraZeneca SHANGHAI, April 18, 2023 /PRNewswire/ -- Shanghai Cellular Biopharmaceutical Group Ltd. (the Company, or Shanghai Cellular Bio), a company engaged in the drug development...

2023-04-18 04:15 2821

Promising Efficacy of AT101 CAR-T for Blood Cancer

SEOUL, South Korea, April 17, 2023 /PRNewswire/ -- AbClon, a South Korean biotech firm, presented non-clinical and phase 1 interim results of its AT101 novel CAR-T therapy at the annual 2023 AACR conference. AT101 targets the CD19 protein for treatment of blood cancer. AT101 demonstrated superio...

2023-04-18 02:00 2391

Promising Efficacy of AT101 CAR-T for Blood Cancer

Asieris Releases 2022 Annual Report: Makes Steady Progress in its Clinical Development, Global Expansion to Treat Genitourinary Tumors, and Implementing its Commercialization Strategy to Provide Integrated Diagnosis-to-Treatment Solutions

SHANGHAI, April 17, 2023 /PRNewswire/ -- Asieris Pharmaceuticals(688176.SH), a global biopharma company specializing in the discovery, development and commercialization of innovative drugs that treat genitourinary (GU) tumors and other related diseases, today released its 2022 annual report. Whil...

2023-04-17 18:30 2748

Telix Reports Q1 2023 Financial Results: Delivers First $100M Revenue Quarter

MELBOURNE, Australia, April 17, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended31 March 2023 (Q1 2023). All figures are in AUD$ unless otherwise st...

2023-04-17 18:15 3365

Bassem Elmankabadi, M.D. joins Foresee Pharmaceuticals as a Senior Vice President of Clinical Development

TAIPEI, April 17, 2023 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), announces today thatBassem Elmankabadi, M.D. joins Foresee as a Senior Vice President of Clinical Development. Dr. Bassem Elmankabadi is a Board Certified Surgeon with over 17 years of clinical backg...

2023-04-17 16:50 2915

Late-Breaking Research - Alphamab Oncology Presents Preclinical Results of KN052 at AACR 2023

SUZHOU, China, April 17, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the preclinical result of KN052 (PD-L1/OX40 bispecific antibody) were presented as a poster at the Late-Breaking Research session of the AACR Annual Meeting 2023 (AACR 2023). The AACR Annual Meet...

2023-04-17 14:01 3061

AffaMed Therapeutics Announces Approval to Initiate a Phase 3 Registrational Clinical Trial in Mainland China for DEXTENZA® for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery

SHANGHAI, April 17, 2023 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global biotechnology company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products that address critical unmet medical needs in ophthalmological, neurological and psychi...

2023-04-17 09:00 5689

Innovent Releases Final Analysis Results of ORIENT-15: the Phase 3 Study of Sintilimab plus Chemotherapy for the First-Line Treatment of Esophageal Squamous Cell Carcinoma at the AACR Annual Meeting 2023

ROCKVILLE, Md. and SUZHOU, China, April 17, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology a...

2023-04-17 08:33 4790

Abbisko presents the research results of 5 programs at the 2023 AACR Annual Meeting

SHANGHAI, April 17, 2023 /PRNewswire/ -- Abbisko (Stock Code: 2256.HK) announced the results of five latest preclinical studies at the 2023 American Association for Cancer Research (AACR) annual meeting. Abbisko These include its self-develo...

2023-04-17 08:30 4591

Abbisko presents the research results of 5 programs at the 2023 AACR Annual Meeting

Innovent Releases Final Analysis Results of ORIENT-15: the Phase 3 Study of Sintilimab plus Chemotherapy for the First-Line Treatment of Esophageal Squamous Cell Carcinoma at the AACR Annual Meeting 2023

ROCKVILLE, Md. and SUZHOU, China, April 16, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology a...

2023-04-17 08:20 3958

Henlius Achieved Steep Revenue Growth in Q1 2023, Core Products Sales Surged

SHANGHAI, April 17, 2023 /PRNewswire/ -- As a global innovative biopharmaceutical company, Henlius is committed to offering high-quality, affordable and innovative biopharmaceuticals to patients worldwide with 5 products launched inChina. Leveraging the differentiated competitive edges of its pr...

2023-04-17 07:45 3674

Bugworks Research Inc. to Present Eight Posters at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) 2023, in Copenhagen, Denmark

BANGALORE, India and DELAWARE CITY, Del. and ADELAIDE, Australia, April 17, 2023 /PRNewswire/ -- Bugworks Research Inc., a clinical-stage biopharmaceutical company, is set to present its latest research findings on the novel bacterial topoisomerase inhibitor, BWC0977 at the upcoming 33rd European...

2023-04-17 07:00 3682

Olaratumab Antibody Licensed from Lilly Demonstrates Proof of Concept as a Theranostic Radiopharmaceutical

MELBOURNE, Australia, April 17, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces successful preclinical development of radiolabelled olaratumab, an antibody licensed from Eli Lilly and Company (Lilly). Telix has demonstrated proof-of-concept (PoC) ...

2023-04-17 06:38 2995

Minghui Pharmaceutical Inc. Announces Phase 2 Clinical Trial Success of MH004 Cream as a Potential Best-in-Class Topical Treatment for Mild-to-Moderate Atopic Dermatitis and the FDA Clearance of its Global Phase 3 MRCT

* Study met both primary and all key secondary endpoints * Mean percentage change from baseline in Eczema Area and Severity Index (EASI) score was -78.7% in 1.0% MH004 Cream-treated group compared to -46.7% in vehicle group * 79.6% individuals treated with 1.0% MH004 Cream achieved EASI-75 c...

2023-04-14 19:00 7482

CytoMed Therapeutics Limited Announces Pricing of Initial Public Offering

SINGAPORE, April 14, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited ("CytoMed" or the "Company"), a pre-clinical biopharmaceutical company focused on harnessing its licensed proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers, today announced ...

2023-04-14 08:00 5261